FGL vs Methylene Blue
A side-by-side research comparison of FGL and Methylene Blue across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FGL | Methylene Blue |
|---|---|---|
| Full name | FGL (NCAM-Derived Peptide) | Methylene Blue (Methylthioninium Chloride) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | FDA-approved (off-label use) |
| Mechanism | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. | Acts as an alternative electron carrier in the mitochondrial electron transport chain, bypassing complex I-III blockades. Inhibits monoamine oxidase, tau aggregation, and provides antioxidant protection through auto-oxidation cycling. |
| Molecular weight | ~1,800 Da | 319.85 Da |
| Half-life | 4-8 hours | 5-6.5 hours |
| Bioavailability | Moderate (SubQ, partial BBB crossing) | ~72% oral |
| Typical dose | 1-5 mg/kg (research) | 0.5-2 mg/kg |
| Frequency | Daily or every other day | Daily or cycled |
| Route | Subcutaneous | Oral solution or sublingual |
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Methylene Blue reported benefits
- Mitochondrial energy boost
- Cognitive enhancement
- Neuroprotection
- Anti-aging at cellular level
- Mood improvement
- Memory support
Related comparisons
Research and educational reference only. Not medical advice.